Falling Oil Prices Don't Give Clean-Energy Stocks the All-Clear

Related Link: 

These are dark days for investors in Big Oil. That doesn’t mean clear skies for investors in clean energy.

Kraft Foods Announces CEO Change

Related Link: 

Kraft Foods said Chairman John Cahill will replace CEO Tony Vernon next week, saying the comany needs to change more quickly amid challenging food industry.

Fears Spread of Sony-Style Hack

Related Link: 

Damaging revelations from the computer assault on Sony are playing like a horror movie in executive suites, prompting companies to review security measures and reconsider what is said in an email.

Deere to Sell Crop-Insurance Ops

Related Link: 

Deere agreed to sell its crop-insurance business to Farmers Mutual Hail Insurance of Iowa, following a strategic review of the unit that began in September.

Playing the Tax 'Audit Lottery'

Related Link: 

Buried in U.S. companies’ securities filings is an indicator for how aggressively they are working to shield their income from the IRS and other tax authorities.

Ports Crisis Brings Commerce to Crawl

Related Link: 

Tommy Bahama and other retailers are a casualty of congestion snarling ports on the West Coast. The logjam in part stems from labor negotiations between port employers and workers.

ConAgra's Profit Plunges on Private-Label Write-Down

Related Link: 

ConAgra Foods said its profit plunged in its November quarter as the company took a large write-down on its struggling private-label segment.

Sony Pulls Korea Film; U.S. Blames Pyongyang for Hack

Related Link: 

Sony Pictures canceled the planned release of “The Interview” after hackers threatened violence against theaters. U.S. officials concluded North Korea was behind the broad cyberattack on the firm.

Drahi Sets Sights on French Weekly

Related Link: 

Franco-Israeli businessman Patrick Drahi is lining up to bid for French weekly magazine L’Express, according to people familiar with the matter, signaling his rising interest in the media business.

AbbVie Pins Hopes on Hepatitis C Treatment

Related Link: 

AbbVie is hoping for regulatory approval this month of its first significant new drug product in a decade: a multidrug regimen for the liver disease hepatitis C. AbbVie currently relies on just one drug to generate 63% of its revenue: the anti-inflammatory drug Humira.

Syndicate content